Patents by Inventor Bjørn Altermark

Bjørn Altermark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of a N-acetylneuraminate lyase derived from the bacterium in the production of neuraminic acid and derivatives thereof
    Patent number: 10378034
    Abstract: The present invention provides to methods for the production of neuraminic acid or derivatives thereof under alkaline conditions and to the use of neuraminate lyases showing improved characteristics under alkaline conditions in the production of neuraminic acid or its derivatives. More particularly, the present invention employs inter alia a N-acetylneuraminate lyase which has been isolated from the psychrophilic bacterium Aliivibrio salmonicida LFI1238 and has shown to have improved characteristics under alkaline conditions.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: August 13, 2019
    Assignee: Universitetet i Tromsø—Norges Arktiske Universitet
    Inventors: Inger Lin Uttakleiv Ræder, Bjørn Altermark, Man Kumari Gurung, Arne Oskar Smalås
  • USE OF A N-ACETYLNEURAMINATE LYASE DERIVED FROM THE BACTERIUM ALIIVIBRIO SALMONICIDA IN THE PRODUCTION OF NEURAMINIC ACID AND DERIVATIVES THEREOF
    Publication number: 20170175155
    Abstract: The present invention provides to methods for the production of neuraminic acid or derivatives thereof under alkaline conditions and to the use of neuraminate lyases showing improved characteristics under alkaline conditions in the production of neuraminic acid or its derivatives. More particularly, the present invention employs inter alia a N-acetylneuraminate lyase which has been isolated from the psychrophilic bacterium Aliivibrio salmonicida LFI1238 and has shown to have improved characteristics under alkaline conditions.
    Type: Application
    Filed: May 27, 2015
    Publication date: June 22, 2017
    Applicant: Universitetet i Tromsø - Norges Arktiske Universitet
    Inventors: Inger Lin Uttakleiv RÆDER, Bjørn ALTERMARK, Man Kumari GURUNG, Arne Oskar SMALÅS
  • Endonucleases
    Patent number: 9650618
    Abstract: The present invention provides an endonuclease I or enzymatically active fragment thereof wherein said endonuclease I has the sequence of SEQ ID No. 4 or a sequence which is at least 70% identical thereto and wherein the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif has been substituted with a residue which is negatively charged as well as nucleic acid molecules encoding these enzymes and methods of removing contaminating polynucleotides from a sample using these enzyme.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: May 16, 2017
    Assignee: BIOTEC PHARMACON ASA
    Inventors: Olav Lanes, Linda Havdalen, Terese Solstad, Marit Lorentzen, Bjørn Altermark, Ingar Leiros, Ronny Helland
  • ENDONUCLEASES
    Publication number: 20160355798
    Abstract: The present invention provides an endonuclease I or enzymatically active fragment thereof wherein said endonuclease I has the sequence of SEQ ID No. 4 or a sequence which is at least 70% identical thereto and wherein the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif has been substituted with a residue which is negatively charged as well as nucleic acid molecules encoding these enzymes and methods of removing contaminating polynucleotides from a sample using these enzyme.
    Type: Application
    Filed: July 15, 2016
    Publication date: December 8, 2016
    Applicant: BIOTEC PHARMACON ASA
    Inventors: Olav LANES, Linda HAVDALEN, Terese SOLSTAD, Marit LORENTZEN, Bjørn ALTERMARK, Ingar LEIROS, Ronny HELLAND
  • Endonucleases
    Patent number: 9422595
    Abstract: The present invention provides an endonuclease I or enzymatically active fragment thereof wherein said endonuclease I has the sequence of SEQ ID No. 4 or a sequence which is at least 70% identical thereto and wherein the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif has been substituted with a residue which is negatively charged as well as nucleic acid molecules encoding these enzymes and methods of removing contaminating polynucleotides from a sample using these enzyme.
    Type: Grant
    Filed: February 18, 2013
    Date of Patent: August 23, 2016
    Assignee: BIOTEC PHARMACON ASA
    Inventors: Olav Lanes, Linda Havdalen, Terese Solstad, Marit Lorentzen, Bjørn Altermark, Ingar Leiros, Ronny Helland
  • Endonucleases
    Publication number: 20140370514
    Abstract: The present invention provides an endonuclease I or enzymatically active fragment thereof wherein said endonuclease I has the sequence of SEQ ID No. 4 or a sequence which is at least 70% identical thereto and wherein the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif has been substituted with a residue which is negatively charged as well as nucleic acid molecules encoding these enzymes and methods of removing contaminating polynucleotides from a sample using these enzyme.
    Type: Application
    Filed: February 18, 2013
    Publication date: December 18, 2014
    Applicant: BIOTEC PHARMACONB ASA
    Inventors: Olav Lanes, Linda Havdalen, Terese Solstad, Marit Lorentzen, Bjørn Altermark, Ingar Leiros, Ronny Helland